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Galectin-3 and β-trace protein 
concentrations are higher in 
clinically unaffected patients with 
Fabry disease
Diana Hernández-Romero1, Jessica Sánchez-Quiñones2, Juan Antonio Vílchez3, 
José Miguel Rivera-Caravaca  1, Gonzalo de la Morena1, Gregory Y. H. Lip4,5, Vicente Climent2 
& Francisco Marín1
Current therapies have not shown benefit in organ damage reversal in Fabry disease (FD), but 
biomarkers could help risk stratification and prognosis. We investigated if several biomarkers of cardiac 
fibrosis, cardiac wall stress, myocardial injury, renal function and inflammation, are associated with 
early cardiac affectation in FD patients. We included FD patients from four cardiology outpatient clinics 
of southeastern Spain. At inclusion, Galectin-3 (Gal-3), N-terminal proB-type natriuretic peptide, high 
sensitivity troponin T (hsTnT), β-trace protein (BTP) and interleukin-6 concentrations were measured. 
The relation of biomarkers concentrations with clinical features, cardiac involvement and organ 
affectation according to the Mainz Severity Score Index (MSSI) was investigated. 44 FD patients (n = 21 
affected and n = 23 unaffected) were compared to age and sex-respectively matched healthy controls. 
Significant differences in biomarkers’ concentration between FD groups were observed. Importantly, 
Gal-3 and BTP levels were higher in unaffected patients when compared with age and sex-matched 
healthy controls (both p < 0.05). All the biomarkers correlated with clinical features. When cut-off 
values for clinical affectation (measured as MSSI ≥ 20) were established, only hsTnT (OR 30.69, 95% CI 
2.70–348.42) and male sex (OR 8.17, 95% CI 1.16–57.75) were independently associated with cardiac 
damage by multivariate regression analysis. Gal-3 and BTP levels are increased in unaffected FD 
patients compared to healthy controls. This suggests that these biomarkers could be useful for the early 
detection of cardiac affectation in FD patients. On the other hand, hsTnT and male sex are independent 
risk factors for established clinical cardiac damage in FD.
Fabry disease (FD) is a rare inherited lysosomal storage disorder linked to the X chromosome. It is character-
ized by a non-metabolized glycosphingolipids progressive accumulation in several tissues. FD can affect many 
different organs showing neurological, cutaneous, ocular, cardiac, gastrointestinal and renal manifestations1–3. 
Published data suggest that heterozygote females present slower and milder progression and expression of the 
disease4,5 although there are reports showing similar severity than to hemizygous males6,7.
Due to the heterogeneity in clinical manifestations of patients with FD, the Mainz Severity Score Index (MSSI) 
was proposed as an attempt to develop a disease-specific scoring system8. This scheme covers different areas 
including cardiac signs and symptoms. Indeed, cardiac manifestations such as arrhythmias, chronic heart failure 
and small vessel disease occur frequently in patients with FD9. In addition, cardiac involvement presenting as 
left ventricular hypertrophy (LVH) caused by myocardial replacement fibrosis is typically observed in advanced 
stages of the disease10.
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Nonetheless, organ and system involvement is progressive in FD, with most patients developing severe kidney 
and heart disease by the third to fifth decade of life11. Despite that the available evidence suggests that specific 
treatment using enzyme replacement therapy (ERT) with recombinant αGAL-A (agalsidase), is able to slow down 
the progression of FD, unfortunately further reversal of organ involvement seems to remain out of reach12. This 
fact supports the importance of future research on the identification of early cardiac damage.
Although several studies evaluating the usefulness of different biomarkers in FD and other cardiomyopa-
thies13–15, no biomarker has proven to be useful in assessing underlying pathophysiological mechanisms, nor 
screen for (or predict) the disease development in FD for earlier initiation of ERT16–18.
Since FD is a progressive disease and current therapies have not shown benefit in organ damage reversal, 
biomarkers of early organ involvement could help risk stratification and help determine prognosis. In the present 
study, we have measured selected biomarkers of different molecular pathophysiological pathways, including car-
diac fibrosis, cardiac wall stress, myocardial injury, renal function and inflammation, in order to investigate if any 
is associated with early cardiac affectation in FD patients.
Material and Methods
We recruited consecutive patients with FD attending cardiology outpatient clinics in four hospitals of the south-
eastern Spain. The diagnosis was performed in all cases by genetic confirmation. We excluded patients with 
hepatic or renal failure (creatinine clearance <50 ml/min), and chronic inflammatory or neoplasic diseases. A 
complete history and clinical examination was performed, including 12-lead electrocardiogram (ECG), standard 
echocardiography, and, when available a blinded cardiac magnetic resonance study. All of these were acquired 
from medical history and electronic medical records. The transthoracic echocardiogram was performed using an 
iE33 ultrasound imager (Philips Medical System, Andover, Massachusetts, United States). For the measurement 
of the linear dimensions of the LV, two-dimensional images of the long axis obtained from a parasternal window 
were used. Regarding the RV, its systolic function was assessed by measuring the systolic displacement of the tri-
cuspid annulus (TAPSE) and was measured from the apical plane of 4 cameras with the M-mode cursor aligned 
on the direction of the lateral tricuspid annulus, according to the current recommendations. By means of pulsed 
Doppler study of transmitral flow velocities in diastole, the filling flow of the LV was studied in the four-chamber 
apical view. All the studies were carried out by a same cardiologist in the same period of the clinical evaluation 
and the extraction of blood samples. Patients were classified according at their clinical involvement into affected 
[left maximal ventricular wall thickness ≥13 mm and/or abnormal ECG (with at least one of the following char-
acteristics: PR < 120 or >200 ms, QRS > 120 ms, inverted T wave or history of significant arrhythmia)] or unaf-
fected (i.e. non-affected) patients. From among the hospital staff and attendees of patients, two different sets 
of age- and sex- matched healthy controls were included, given the large gap in age and sex detected between 
affected and unaffected patients. Thus, affected patients were compared against one set of matched controls, and 
unaffected patients were compared against another set of matched controls.
The MSSI was used to evaluate the clinical involvement in FD patients and was calculated at inclusion. The 
MSSI scheme is composed of four sections covering general, neurological, cardiovascular and renal signs and 
symptoms of FD8. We used this tool to evaluate usefulness of biomarkers for clinical cardiac implication based on 
this accepted score in FD patients.
The study was carried out according to the principles of the Declaration of Helsinki and was approved by the 
Ethics Committee of the Instituto de Investigación Sanitaria y Biomédica de Alicante and the Ethics Committee 
of the Hospital Clínico Universitario Virgen de la Arrixaca. All included patients gave written informed consent 
to participation.
Blood samples and laboratory assays. At inclusion, a >12 hours fasting venipuncture was performed 
in all patients. Plasma and serum fractions were obtained by centrifugation for 15 minutes at 3500 g. Aliquots 
were stored at −40 °C to allow batch analysis in a blinded fashion. We determined selected biomarkers of car-
diac fibrosis (Galectin-3, Gal-3), cardiac wall stress (N-terminal proB-type natriuretic peptide, NT-proBNP), 
myocardial injury (high sensitivity troponin T, hsTnT), renal function (β-trace protein, BTP) and inflammation 
(interleukin-6, IL-6).
Gal-3 levels were determined on defrosted serum samples by ELFA (Enzyme-Linked Fluorescent Assay) in a 
Mini Vidas analyzer (Biomérieux®, France). The inter-assay and intra-assay coefficients of variation were 6.5% 
and 1.6%, respectively. The assay range was 3.3–100 ng/mL, with a lower limit of detection of 2.2 ng/mL and the 
limit of quantification at 3.3 ng/mL.
Serum levels of hsTnT were assayed by a Cobas® 6000 analyser (Roche Diagnostics, Mannheim, Germany). 
The inter-assay variation for hsTnT determining was 2.4%, with a lower detection limit of 3 ng/L.
Serum NT-proBNP was determined using a Roche Diagnostics proBNP assay on an Elecys 2010 analyzer 
(Roche Diagnostics, Mannhein, Germany) with an inter-assay variation of 3.5% and a detection limit of 5 pg/mL.
The determination of BTP was performed using a BN ProSpec analyzer (Dade Behring, Liederbach, 
Germany). The intra-assay and inter-assay coefficients of variation were 2.8% and 4.7%. Regarding renal function, 
it is important to note that the Modification of Diet in Renal Disease (MDRD-4) equation was used to estimate 
the Glomerular Filtration Rate (GFR) and the results were expressed in mL/min/1.73 m2.
Finally, concentrations of IL-6 were determined using Cobas® 6000 analyser (Roche Diagnostics, Mannheim, 
Germany). Within-run and total coefficients of variation of assays were <2% and 4.9%, respectively.
Statistical analysis. First, we calculated sample size for testing biomarkers differences and a probability of 
a type-I error (alpha error) of 5% (0.05). The selected type-II error (β error) and the study power (Power = 1 − β) 
were 20% (0.2) and 80%, respectively. Our sample calculations demonstrated that a minimum of 19 subjects in 
each (patient or healthy control) arm was necessary.
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Regarding the statistical analyses, categorical variables are presented as counts (percentages), while continu-
ous variables are presented as mean ± SD (standard deviation) or median (interquartile range, IQR), as appropri-
ate. The Kolmogorov-Smirnov test was used to check for normal distribution of continuous data.
Clinical variables were studied by bivariate correlations with the selected biomarkers. Receiver Operating 
Characteristic (ROC) curves were performed for evaluation of biomarkers levels related to patient’s organ 
involvement with the MSSI ≥ 20. Cut-off values were selected as the concentration of each biomarker with the 
best combination of sensitivity and specificity from ROC curves according to the Youden Index.
Univariate logistic regression analyses were performed to evaluate association between the selected cut-off of 
the biomarkers, as well as demographic or clinical variables, with cardiac involvement as assessed by the above 
indicated clinical parameters. Variables showing p-values < 0.15 where included into a multivariate regression 
model. Linear regression was used to show correlations between MSSI sub-scores and biomarker’s values. All 
p-values < 0.05 were accepted as statistically significant. Statistical analysis was performed using SPSS 19.0 for 
Windows (SPSS, Inc., Chicago, IL, USA).
Results
We included 44 patients who were diagnosed with FD based on a molecular genetic analysis showing het-
erozygous or hemizygous mutation in the α-GAL-A-gene (GLA) as follows: 18 patients carrying mutation 
p.S238N (c.9091G > A), 10 showing mutation g.5052_5079del28, 4 with the mutation p.M187R, 4 patients 
with c.194 + 39delAT, 3 with p.W226C (c.226G > T) and p.R227X (c.227C > T), 2 patients carrying mutation 
p.Arg227x (c.679C > T), 2 showing mutation p.S126G (c.376A > G) and 1 patients with p.I253T(c.758T > C). 
Patients were classified attending their cardiac clinical phenotype into cardiac involvement (LVH or ECG abnor-
malities) or unaffected (without clinical manifestation or involvement). Table 1 summarizes baseline characteris-
tics of both patients’ types. As expected, those affected patients were significantly older and predominantly males. 
Differences in ERT, New York Heart Association (NYHA) functional class, GFR, history of atrial fibrillation, LVH 
and left ventricular maximum wall thickness (LVMT), α-Galactosidase activity and Lyso-Gb3 levels or MSSI 
were present between the two cohorts (all < 0.05).
Concentration of biomarkers and correlation with clinical features. Table 2 shows biomarkers 
concentrations for each biomarker and cohort. All biomarkers were significantly increased in affected patients 
in comparison with unaffected patients. Similar results were obtained when analyzing only male patients 
(Supplementary Table 1). As expected, affected patients had also higher concentrations of all biomarkers com-
pared to age and sex-matched healthy controls. Of note, we found that Gal-3, BTP and IL-6 levels were higher 
in unaffected patients when compared with age and sex-matched healthy controls (p = 0.018, p < 0.001 and 
p = 0.036, respectively) (Table 2).
We evaluated clinical features and differences in conventional echocardiographic parameters were found 
between affected and unaffected patients (Supplementary Table 2). Regarding correlations of biomarkers with 
clinical features, all of them demonstrated positive significant results for NYHA, LVH and LVMT (Table 3). 
Additionally, indexed left ventricular mass (ILVM) correlated with Gal-3, NT-proBNP, IL-6 and BTP, whereas 
glomerular filtration rate showed a significant negative correlation with Gal-3, NT-proBNP, hsTnT and BTP. Left 
ventricular ejection fraction (LVEF) did not correlate with any of the biomarkers, and Tricuspid Annular Plane 
Systolic Excursion (TAPSE), as marker of right ventricular systolic function, only negatively correlated with Gal-3 
levels. All measured biomarkers correlated each other, with the exception of IL-6 and BTP (Table 3).
Affected patients
(N = 21)
Unaffected patients
(N = 23) p-value
Age (years) 52.2 ± 11.4 38.4 ± 18.3 0.004
Male 15 (71.4) 6 (26.1) 0.006
ERT 16 (76.2) 5 (21.7) 0.001
α-Galactosidase activity 15.46 ± 9.95 47.12 ± 27.84 0.001
Lyso-Gb3 (mg/mL) 5.57 (4.40–9.24) 1.56 (0.76–3.12) 0.003
NYHA functional class ≥2 11 (52.4) 1 (4.3) 0.002
Previous MI 1 (4.8) 0 (0.0) 0.447
GFR 65.1 ± 47.5 112.0 ± 31.2 0.001
Albumin-to-creatinine ratio (mg/g) 14.3 (0.75–14.5) 4.0 (1.4–7.4) 0.018
Hypertension 11 (52.4) 5 (26.1) 0.121
Previous AF 5 (23.8) 0 (0.0) 0.021
LV hypertrophy 20 (95.2) 1 (4.3) <0.001
ICD 3 (14.3) 0 (0.0) 0.100
LV maximum wall thickness 15.5 ± 6.1 11.4 ± 5.6 0.025
MSSI 18 (15–20.5) 3 (1–5) 0.011
Table 1. Baseline characteristics. AF = atrial fibrillation; ERT = enzyme replacement therapy; 
GFR = glomerular filtration rate (by the 4-variable Modification of Diet in Renal Disease [MDRD-4], equation); 
ICD = implantable cardioverter defibrillator; LV = left ventricular; MI = myocardial infarction; MSSI = Mainz 
Severity Score Index; NYHA = New York Heart Association.
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Cut-off points associated with clinical cardiac involvement. In order to establish cut-off points asso-
ciated with clinical cardiac involvement, we constructed ROC curves for biomarkers’ levels depending on the 
affectation measured as MSSI score >20 (Supplementary Fig. 1). When the analysis was performed for Gal-3 
levels, we selected a cut-off point of 9.5 ng/mL, with a sensitivity value of 1.00 and a specificity value of 0.70. As 
for NT-proBNP levels, the selected cut-off point was 206.4 pg/mL, with a sensitivity and specificity values of 1.00 
and 0.88, respectively. Regarding hsTnT, ROC analysis showed a cut-off point (sensitivity, specificity) of 12.42 pg/
mL (1.00–0.82). For BTP, the best cut-off (sensitivity, specificity) value was 0.81 mg/L (0.86, 0.88). Finally, corre-
sponding figures for IL-6 were 1.57 pg/mL (0.71, 0.85).
Using these cut-off points all biomarkers with the exception of Gal-3 were significantly associated with cardiac 
clinical involvement, as defined by or clinical criteria, on univariate analyses. In addition, age, male sex and GFR 
were also associated with clinical cardiac involvement. However, on multivariate analysis, only hsTnT (OR 30.69, 
95% CI 2.70–348.42; p = 0.006) and male sex (OR 8.17, 95% CI 1.16–57.75; p = 0.035) remained independently 
associated (Table 4).
Biomarkers for global and organ affectation with MSSI. As shown in Fig. 1, Gal-3, NT-proBNP and 
hsTnT levels were significantly higher in patients with MSSI ≥ 20 (p-values = 0.005; 0.003 and 0.005, respec-
tively), whereas BTP showed a non-significant trend (p = 0.065) and IL-6 did not demonstrate to be significantly 
increased in patients with MSSI ≥ 20.
As it is already stated in Methods, the MSSI is composed of four sub-scores. Thus, Gal-3 levels were associated 
with cardiac and renal involvement sub-scores (both p < 0.001). On the other hand, NT-proBNP and hsTnT levels 
were associated with general (both p < 0.001), cardiac (p = 0.001 and p < 0.001, respectively) and renal (p = 0.014 
and p = 0.001, respectively) subsections. Finally, BTP levels were associated with cardiac (p = 0.001) and renal 
sub-scores (p < 0.001) whereas IL-6 levels were only associated with cardiac sub-score (p = 0.011) (Table 5).
Affected patients
(N = 21)
Unaffected patients
(N = 23) p-value
Healthy controls 1
(N = 46) p-value*
Healthy controls 2
(N = 27) p-value**
Gal-3 16.6 ± 6.3 11.2 ± 2.7 0.004 10.9 ± 2.5 0.002 9.6 ± 1.8 0.018
NT-proBNP 1056.0 (69.4–2922.5) 50.2 (28.3–90.1) <0.001 33.8 (19.8–61.9) <0.001 31.7 (19.6–54.9) 0.089
hsTnT 25.3 (12.3–62.1) 4.5 (3.3–7.0) <0.001 5.9 (4.0–8.2) <0.001 4.7 (3.6–7.6) 0.516
BTP 0.83 (0.64–1.2) 0.62 (0.56–0.68) 0.001 0.52 (0.48–0.57) <0.001 0.51 (0.47–0.53) <0.001
IL-6 1.5 (1.5–2.6) 1.5 (1.5–1.5) 0.006 1.5 (1.5–1.5) 0.001 1.5 (1.5–1.5) 0.036
Table 2. Comparative analysis for biomarkers values between affected and unaffected patients and their 
respective healthy controls. *Compared to affected patients. **Compared to unaffected patients. Healthy controls 
1 = age and sex-matched to affected patients; Healthy controls 2 = age and sex-matched to unaffected patients.
Clinical Feature or 
Biomarker
Gal-3 NT-proBNP hsTnT IL-6 BTP
r p-value r p-value r p-value r p-value r p-value
New York Heart 
Association 0.50 0.001 0.53 <0.001 0.55 <0.001 0.40 0.010 0.50 0.001
LV hypertrophy 0.53 <0.001 0.61 <0.001 0.75 <0.001 0.41 0.008 0.40 0.010
LV maximum wall 
thickness 0.32 0.047 0.49 0.001 0.61 <0.001 0.43 0.006 0.52 0.001
Indexed left 
ventricular mass* 0.86 <0.001 0.39 0.019 0.25 0.127 0.57 <0.001 0.51 0.002
LV ejection 
fraction** −0.26 0.111 −0.09 0.588 −0.29 0.064 −0.06 0.705 −0.16 0.328
TAPSE −0.50 0.019 −0.12 0.558 −0.21 0.318 −0.25 0.260 −0.13 0.558
Glomerular filtration 
rate −0.57 0.002 −0.67 <0.001 −0.64 <0.001 −0.24 0.245 −0.44 0.025
Gal-3 — — — — —
NT-proBNP 0.43 0.004 — — — —
hsTnT 0.75 <0.001 0.64 <0.001 — — —
IL-6 0.38 0.015 0.52 0.001 0.40 0.010 — —
BTP 0.62 <0.001 0.33 0.037 0.54 <0.001 0.29 0.074 —
Table 3. Correlations between biomarkers and clinical features. LV = left ventricular; TAPSE = Tricuspid 
Annular Plane Systolic Excursion. *The mass of the left ventricle in grams was calculated by the linear method 
from the diameters and ventricular thicknesses with the formula = 0.8 × {1.04 × [([left ventricular end-diastolic 
dimension + interventricular septal thickness at end-diastole + posterior wall thickness at end-diastole]3-left 
ventricular end-diastolic dimension3)]} + 0.6. **Measured with Simpson biplane method (apical four and two 
cameras).
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Discussion
FD is a multiorganic disease affecting different systems such as cardiovascular, neurologic or renal. In the present 
study we have evaluated biomarkers for cardiac fibrosis (Gal-3), cardiac wall stress (NT-proBNP), myocardial 
injury (hsTnT), renal function (BTP) or inflammation (IL-6) in patients with FD. In summary, we found differ-
ences in all the measured biomarkers between affected and non-affected patients.
One of our main results is that three measured biomarkers (Gal-3, BTP and IL-6) appeared higher in clinically 
non-affected patients than in matched controls, suggesting their potential usefulness for early detection of cardiac 
affectation. Until now, only clinical tools are available for evaluation of affectation signs in Fabry patients. We 
hereby demonstrate that the mentioned biomarkers are higher in patients showing no clinical involvement when 
compared with age and sex-matched controls. However, given that IL-6 showed the majority of values under 
the detection limit, it seems not to be the biomarker of choice for this purpose, despite its statistically significant 
differences.
In addition, when attending at the cardiac clinical affectation into the patients’ cohort, we found that all the 
analysed biomarkers were raised in the affected versus unaffected patients. Patients within the unaffected group 
were younger and predominantly female, as has been previously described18–20.
In our study, all biomarkers with the exception of IL-6 correlated with functional class (NYHA functional 
class), renal function (GFR) or cardiac hypertrophy (LVH or IVM). Gal-3 was the best biomarker for clinical 
cardiac involvement, and was significantly associated with the whole spectrum of the studied correlations. This 
biomarker has been proposed as biomarker of fibrosis or remodelling21, and it is higher in patients with lysosomal 
diseases22. We therefore propose that Gal-3 may be implicated in the early stages of organ involvement in patients 
with FD, including cardiac or renal remodelling, as suggested by the strong association with MSSI sub-scores 
and all the parameters of clinical involvement. This hypothesis is also supported by our observation that Gal-3, 
together with BTP, was significantly higher in the unaffected versus healthy control group. Hence, both biomark-
ers could be useful for early detection of sub-clinical affectation or for therapy follow-up.
Here, we have also proposed a cut-off point for each biomarker of cardiac clinical affectation. By applying our 
criteria and the accepted MSSI for FD patients, only hsTnT and male sex were independently associated in the 
multivariate analysis. Our group previously reported that hsTnT remains high in patients with stable hypertrophic 
cardiomyopathy (HCM), indicating that this biomarker may reflect a continuous myocyte loss associated with 
parameters of HCM severity23. Previous studies reported higher concentrations of TnI in FD compared with 
healthy controls, associated with LVH24. In addition, Seydelmann et al.25 found that increased hsTnT levels in FD 
patients with advanced cardiomyopathy were highly correlated with fibrosis detected on cardiac magnetic reso-
nance imaging. Other groups, have demonstrated that also biomarkers of endothelial dysfunction such symmet-
ric dimethylarginine (SDMA) and L-homoarginin/SDMA may be involved in Fabry related cardiomyopathy26.
Herein we also demonstrate that Gal-3 and BTP were associated with cardiac and renal impairment and they 
are higher in patients at early stages of organ involvement. In advanced affected patients, hsTnT emerges an inde-
pendent risk factor for clinical cardiac involvement, together with male sex, with values of hsTnT ≥12.42 pg/mL 
as potential useful cut-off for the prediction of clinical cardiac involvement.
Limitations. This study is limited mainly by its observational design so we could explore only associations, 
and no causality is implied. Although biomarkers’ levels resulted clearly higher in affected patients, we cannot 
ignore possible changes in their levels over time. In addition, we cannot exclude the involvement of other vari-
ables not included in the present study. Another limitation that must be acknowledged is the sample size, since 
FD is a rare, progressive disease. Larger cohorts, perhaps from multicentre international studies, are desirable to 
corroborate our results.
Biomarker* or Clinical Feature
Univariate Analysis
Multivariate Analysis
(conditional mode)
OR (95% CI); p-value OR (95% CI); p-value
Gal-3 (Cut-off point; Sensitivity-Specificity)
9.5 ng/mL; (1.00–0.70) 2.04 (0.44–9.34); 0.361
NT-proBNP (Cut-off point; Sensitivity-Specificity)
206.4 pg/mL; (1.00–0.88) 40.86 (4.51–370.44); 0.001 3.93 (0.19–81.60); 0.116
hsTnT (Cut-off point; Sensitivity-Specificity)
12.42 pg/mL; (1.00–0.82) 198.00 (16.58–2364.88); <0.001 30.69 (2.70–348.42); 0.006
BTP (Cut-off point; Sensitivity-Specificity)
0.81 mg/L; (0.86–0.88) 24.75 (2.69–227.61); 0.005 1.74 (0.11–27–24); 0.597
IL-6 (Cut-off point; Sensitivity-Specificity)
1.57 pg/mL; (0.71–0.85) 9.33 (1.65–52.92); 0.012 3.76 (0.13–106.42); 0.095
Age 1.06 (1.04–1.11); 0.011 1.05(0.94–1.18); 0.179
Male sex 7.08 (1.88–26.72); 0.004 8.17 (1.16–57.75); 0.035
Glomerular filtration rate 10.3 (1.01–1.06); 0.005 0.99 (0.95–1.05); 0.454
Table 4. Logistic regression analysis for cardiac affectation. *Selected cut-off points and Sensitivity/1-
Specificity parameters form ROC curves for clinical affectation (Mainz Severity Score Index ≥ 20). 
CI = Confidence Interval; OR = Odds Ratio.
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Conclusion
In the present study we demonstrate that Gal-3 and BTP levels are significantly increased in clinically unaffected 
patients with FD in comparison with healthy controls. This finding suggests that these biomarkers could be use-
ful for the early detection of cardiac affectation in patients with FD. On the other hand, hsTnT and male sex are 
independent risk factors for established clinical cardiac involvement in FD.
Figure 1. Concentration of biomarkers depending on Fabry disease patients’ global affectation (measured by MSSI).
MSSI sub-score β coef. (95% CI) p-value
Gal-3
General 0.98 (−0.41–2.67) 0.162
Neurological −0.23 (−0.79–0.33) 0.406
Cardiac 0.51 (0.32–0.70) <0.001
Renal 0.58 (0.34–0.82) <0.001
NT-proBNP
General 823.82 (629.84–1037.81) <0.001
Neurological 118.80 (−111.23–348.71) 0.303
Cardiac 170.82 (74.51–207.11) 0.001
Renal 161.73 (35.01–288.40) 0.014
hsTnT
General 7.58 (3.99–11.17) <0.001
Neurological 1.89 (−1.04–4.81) 0.200
Cardiac 3.05 (2.01–4.09) <0.001
Renal 2.68 (1.15–4.21) 0.001
BTP
General 0.05 (−0.08–0.18) 0.436
Neurological −0.02 (−0.05–0.05) 0.934
Cardiac 0.04 (0.01–0.06) 0.001
Renal 0.06 (0.04–0.08) <0.001
IL-6
General 0.05 (−0.13–0.23) 0.575
Neurological −0.03 (−0.10–0.04) 0.402
Cardiac 0.04 (0.01–0.07) 0.011
Renal 0.03 (−0.01–0.06) 0.196
Table 5. Linear regression analysis for organ involvement. CI = confidence interval; MSSI = Mainz Severity 
Score Index; OR = odds ratio.
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